Announced
Synopsis
Cheplapharm Arzneimittel, a German pharmaceutical company, agreed to acquire Astellas Pharma's Products Rights for five legacy products in Europe, Russia, CIS, and Asia for €95m. After closing of the investment, which is scheduled for September 2021, Cheplapharm will take over the marketing authorizations for the products in close collaboration with Astellas in order to ensure continuity of supply for these key medicines forpatients.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.